Comparison of Insulin Mix25 Versus Mix50 (CLASSIFY)

• Percentage of Participants Achieving HbA1c of <7% or ≤6.5% at 26 Weeks [ Time Frame: 26 Weeks ] [ Designated as safety issue: No ]
• Change from Baseline in Fasting Serum Glucose at 26 Weeks [ Time Frame: Baseline, 26 Weeks ] [ Designated as safety issue: No ]
• Change from Baseline in Body Weight at 26 Weeks [ Time Frame: Baseline, 26 Weeks ] [ Designated as safety issue: No ]
• Number of Hypoglycemic Events at 26 Weeks (Incidence) [ Time Frame: 26 Weeks ] [ Designated as safety issue: Yes ]
• Insulin Dose at 26 Weeks [ Time Frame: 26 Weeks ] [ Designated as safety issue: No ]
• Change from Baseline in 1,5-Anhydroglucitol (1,5-AG) at 26 Weeks [ Time Frame: Baseline, 26 Weeks ] [ Designated as safety issue: No ]

The purpose of this study is to determine the efficacy and safety of insulin Lispro Mix25 (LM25) compared to insulin Lispro Mix50 (LM50) as an insulin starter in participants with Type 2 diabetes mellitus (T2DM).

• Drug: Insulin Lispro Mix25
  Administered SC
  Other Name: LY275585-75
• Drug: Insulin Lispro Mix50
  Administered SC
  Other Name: LY275585-50

• Experimental: Insulin Lispro Mix25
  Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
  Intervention: Drug: Insulin Lispro Mix25
• Experimental: Insulin Lispro Mix50
  Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.
  Intervention: Drug: Insulin Lispro Mix50

Inclusion Criteria:

• Have a diagnosis of Type 2 Diabetes Mellitus for at least 6 months
• Have been taking sulfonylureas, biguanide, thiazolidinedione, alpha-glucosidase inhibitor, glinide, or dipeptidyl peptidase IV inhibitor, or any combination of these
• Have a qualifying hemoglobin A1c value ≥7.0% and ≤11.0% at screening
• Have a body mass index (BMI) ≥18.5 and <35.0 kilogram per square meter (kg/m^2)
• Have given written informed consent to participate in the study in accordance with local regulations and the ethical review board (ERB) governing the study site

Exclusion Criteria:

• Have a diagnosis of type 1 diabetes
• Have had more than 1 episode of severe hypoglycemia within the 6 months before screening
• Have any of the following cardiovascular conditions within 3 months prior to screening: acute myocardial infarction, New York Heart Association class III or class IV heart failure, or cerebrovascular accident (stroke)
• Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase levels ≥3.0 times the upper limit of the reference range at screening, as determined by the central laboratory
• Have an estimated creatinine clearance (CrCl), Cockcroft-Gault formula <30 milliliter per minute (mL/min), as determined by the central laboratory at screening
• Have evidence of a significant, active, uncontrolled endocrine or autoimmune abnormality, as judged by the investigator
• Have an active or untreated malignancy or have been in remission from a clinically significant malignancy for <5 years
• Have any other condition (such as, known drug or alcohol abuse or a psychiatric disorder) that may prevent the participants from following and completing the protocol
• Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study